The present invention pertains to 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide or a pharmaceutically acceptable salt thereof, or 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoro-methyl)phenyl]benzamide or a pharmaceutically acceptable salt thereof, for the treatment of disorders mediated by alpha-carbonic anhydrase isoforms selected from intraocular hypertension (glaucoma), epilepsy, Lennox-Gastaut syndrome, altitude sickness, headaches, neurological disorders and obesity.本發明係關於一種4-(4-甲基哌嗪-1-基甲基)-N-[4-甲基-3-(4-吡啶-3-基)嘧啶-2-基胺基)苯基]-苯甲醯胺或其醫藥上可接受的鹽,或4-甲基-3-[[4-(3-吡啶基)-2-嘧啶基]胺基]-N-[5-(4-甲基-1H-咪唑-1-基)-3-(三氟甲基)苯基]苯甲醯胺或其醫藥上可接受的鹽,其係用於治療由α-碳酸酐酶之異形體調節之選自高眼壓症(青光眼)、癲癇、Lennox-Gastaut症候群、高山症、頭痛、神經紊亂及肥胖之疾病。
